Additional treatment prolonged survival of pulmonary artery sarcoma after surgical resection | Zendy

Liwei Xu | Zendy; Weishan Lu | Zendy; Jianqiang Li | Zendy; Changchun Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Additional treatment prolonged survival of pulmonary artery sarcoma after surgical resection

Author(s) -

Liwei Xu,

Weishan Lu,

Jianqiang Li,

Changchun Wang

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.02.80

Subject(s) - medicine , hazard ratio , surgery , metastasis , confidence interval , sarcoma , adjuvant therapy , retrospective cohort study , survival rate , chemotherapy , cancer , pathology

Pulmonary artery sarcoma (PAS) is an extremely rare malignant tumor, that was first described by Mandelstamm in 1923 (1). Surgical intervention is the mainstay in the treatment for PAS, but the postoperative prognosis remains poor (2). The effect of adjuvant and/or neo-adjuvant chemotherapy and radiotherapy for PAS are controversial (3,4). However, PAS is very rare and there is currently no randomized controlled trial on adjuvant and/or neoadjuvant chemotherapy for PAS. In this study, to analyze the therapeutic effect of adjuvant therapy on postoperative survival time, we searched MEDLINE and EMBASE database, reviewed a total of 1397 articles published from 1932 to 2018, and selected 162 articles (275 cases). Original Article

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research